Regenxbio Inc
RGNX8.386USD
+0.196+2.39%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
420.29MCap. mercado
PérdidaP/E TTM
Más Datos de Regenxbio Inc Compañía
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Información de la empresa
Símbolo de cotizaciónRGNX
Nombre de la empresaRegenxbio Inc
Fecha de salida a bolsaSep 17, 2015
Director ejecutivoMr. Curran M. Simpson
Número de empleados353
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 17
Dirección9804 Medical Center Drive
CiudadROCKVILLE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal20850
Teléfono12405528181
Sitio Webhttps://regenxbio.com/
Símbolo de cotizaciónRGNX
Fecha de salida a bolsaSep 17, 2015
Director ejecutivoMr. Curran M. Simpson
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
58.87K
--
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-55.17%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
31.47K
-13.00%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+63.21%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+68.83%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+68.83%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
17.82K
--
Mr. Allan M. Fox, J.D.
Mr. Allan M. Fox, J.D.
Director
Director
--
--
Dr. David C. (Dave) Stump, M.D.
Dr. David C. (Dave) Stump, M.D.
Independent Director
Independent Director
--
--
Dr. A. N. (Jerry) Karabelas, Ph.D.
Dr. A. N. (Jerry) Karabelas, Ph.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
58.87K
--
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-55.17%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
31.47K
-13.00%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
20.06K
+63.21%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
19.05K
+68.83%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
19.05K
+68.83%
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Redmile Group, LLC
9.52%
BlackRock Institutional Trust Company, N.A.
7.77%
The Vanguard Group, Inc.
6.89%
JP Morgan Asset Management
5.85%
Fox (Allan Mark)
5.76%
Other
64.21%
Accionistas
Accionistas
Proporción
Redmile Group, LLC
9.52%
BlackRock Institutional Trust Company, N.A.
7.77%
The Vanguard Group, Inc.
6.89%
JP Morgan Asset Management
5.85%
Fox (Allan Mark)
5.76%
Other
64.21%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor/Hedge Fund
29.45%
Investment Advisor
29.40%
Hedge Fund
17.30%
Research Firm
8.25%
Individual Investor
7.69%
Sovereign Wealth Fund
2.96%
Pension Fund
0.32%
Bank and Trust
0.25%
Family Office
0.10%
Other
4.27%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
421
48.24M
95.74%
-3.52M
2025Q1
446
48.46M
96.35%
-3.90M
2024Q4
444
48.16M
97.22%
-4.82M
2024Q3
444
49.64M
100.43%
-4.45M
2024Q2
437
49.30M
99.98%
-3.20M
2024Q1
451
48.23M
99.21%
+414.63K
2023Q4
436
43.62M
98.84%
-7.14M
2023Q3
439
43.73M
99.56%
-6.26M
2023Q2
439
43.86M
100.57%
-5.31M
2023Q1
456
44.07M
101.46%
-1.49M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Redmile Group, LLC
4.79M
9.52%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.92M
7.77%
+48.66K
+1.26%
Mar 31, 2025
The Vanguard Group, Inc.
3.47M
6.89%
+495.83K
+16.65%
Mar 31, 2025
JP Morgan Asset Management
2.95M
5.85%
+36.88K
+1.27%
Mar 31, 2025
Fox (Allan Mark)
2.90M
5.76%
+7.77K
+0.27%
May 30, 2025
Morgan Stanley & Co. LLC
1.57M
3.11%
+45.10K
+2.96%
Mar 31, 2025
Balyasny Asset Management LP
1.40M
2.78%
+211.40K
+17.81%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
1.15M
2.28%
-23.70K
-2.02%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.11M
2.2%
+12.72K
+1.16%
Mar 31, 2025
BlackRock Financial Management, Inc.
1.09M
2.17%
-19.59K
-1.76%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
WisdomTree BioRevolution Fund
1.81%
iShares Neuroscience and Healthcare ETF
0.92%
Virtus LifeSci Biotech Clinical Trials ETF
0.72%
Global X Genomics & Biotechnology ETF
0.48%
JPMorgan Fundamental Data Science Small Core ETF
0.34%
ALPS Medical Breakthroughs ETF
0.28%
SPDR S&P Biotech ETF
0.13%
iShares Health Innovation Active ETF
0.08%
Direxion Daily S&P Biotech Bull 3X Shares
0.07%
Fidelity Enhanced Small Cap ETF
0.07%
Ver más
WisdomTree BioRevolution Fund
Proporción1.81%
iShares Neuroscience and Healthcare ETF
Proporción0.92%
Virtus LifeSci Biotech Clinical Trials ETF
Proporción0.72%
Global X Genomics & Biotechnology ETF
Proporción0.48%
JPMorgan Fundamental Data Science Small Core ETF
Proporción0.34%
ALPS Medical Breakthroughs ETF
Proporción0.28%
SPDR S&P Biotech ETF
Proporción0.13%
iShares Health Innovation Active ETF
Proporción0.08%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.07%
Fidelity Enhanced Small Cap ETF
Proporción0.07%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
